Referencias
1. Jones CM, Mack KA, Paulozzi LJ: Pharmaceutical overdose deaths, United States, 2010. JAMA 2013;309(7):657-9.
2. FDA: Abuse deterrent opioids - evaluation and labeling guidance for industry. In: U.S. Department of Health and Human Services, F.A.D.A., Center for Drug Evaluation and Research (CDER) (ed); 2015.
3. Cicero TJ, Ellis MS. Abuse deterrent formulations and the prescription opioid epidemic in the United States: Lessons learned from Oxycontin. JAMA Psychiatry 2015;72(5):424-30.
4. Brown Jr RE. Abuse-deterrent formulations of opioids: Many questions still to answer. J Opioid Manag 2017;13(6):353-6.
5. Setnik, B. Opioid overdose protection: an inevitable need to address an alarming epidemic. J Opioid Manag 2017;13(6):363-4.
6. Dart RC, Iwanicki JL, Dasgupta N, Cicero TJ, Schnoll SH. Do abuse deterrent opioid formulations work? J Opioid Manag 2017;13(6):365-77. DOI: 10.5055/jom.2017.0415.
7. Hale ME, Moe D, Bond M, Gasior M, Malamut R. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag 2016;6(5):497-508.